HLS Therapeutics (TSE:HLS) Sets New 12-Month Low – Here’s What Happened

Shares of HLS Therapeutics Inc. (TSE:HLS) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as C$3.71 and last traded at C$3.75, with a volume of 37404 shares traded. The stock had previously closed at C$3.90.

Analyst Ratings Changes

A number of research analysts have recently commented on HLS shares. Canaccord Genuity Group raised HLS Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 13th. Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from C$7.00 to C$8.00 in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Strong Buy” and a consensus price target of C$8.00.

HLS Therapeutics Price Performance

The stock has a market capitalization of C$116.97 million, a price-to-earnings ratio of -13.85 and a beta of -0.18. The company has a quick ratio of 1.01, a current ratio of 1.05 and a debt-to-equity ratio of 75.86. The business has a 50-day simple moving average of C$4.20 and a two-hundred day simple moving average of C$4.40.

HLS Therapeutics (TSE:HLS) last issued its quarterly earnings results on Wednesday, August 12th. The company reported C($0.03) earnings per share (EPS) for the quarter. HLS Therapeutics had a negative net margin of 15.26% and a negative return on equity of 14.39%. The firm had revenue of C$14.67 million for the quarter. During the same quarter in the previous year, the business posted ($0.09) EPS. As a group, research analysts predict that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.